Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481557 · ClinicalTrials.gov registry record · NA
Effects of an Oxalate Containing Product on Dentinal Hypersensitivity With Dental Prophylaxis
A NA study, sponsored by Procter and Gamble.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT02481557: Completed NA study, sponsored by Procter and Gamble.
NCT02481557 is a NA study that has completed, run by Procter and Gamble. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02481557, a NA study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study will assess sensitivity during a dental prophylaxis with or without the use of a potassium oxalate salt solution.
Primary Outcome
The Schiff Sensitivity Scale was assessed for each test tooth via an evaporative air challenge. The examiner recorded the Schiff Index score corresponding to the response to the air challenge. The Schiff Index Sensitivity scale is scored as follows- 0: tooth/subject did not respond to stimulus, 1: tooth/subject responds to stimulus, but does not request discontinuation of stimulus, 2: tooth/subject responds to stimulus and requests discontinuation or moves form stimulus, 3: tooth/subject respond
Interventions
- DEVICE Oxalate Salt Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-06 |
| Phase | NA |
What the finished NCT02481557 record still lists
NCT02481557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Oxalate Salt Solution is the first listed.
NCT02481557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02481557 about?
NCT02481557 is a clinical study titled "Effects of an Oxalate Containing Product on Dentinal Hypersensitivity With Dental Prophylaxis". This study will assess sensitivity during a dental prophylaxis with or without the use of a potassium oxalate salt solution.
What is the current status of trial NCT02481557?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2015-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02481557?
The interventions under investigation include: Oxalate Salt Solution (DEVICE).
Who is sponsoring clinical trial NCT02481557?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02481557's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia